search

Active clinical trials for "Diabetic Nephropathies"

Results 21-30 of 427

SER150 vs Placebo in Diabetic Kidney Disease

Diabetic Kidney Disease

This study is to assess the efficacy, safety and pharmacokinetic (PK) of SER150 administered for 24 weeks as a 15 mg twice a day (BID) dose in participants with type 2 diabetes (T2D) and macroalbuminuria in treatment with either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor antagonist (ARB).

Recruiting34 enrollment criteria

NAD Augmentation in Diabetes Kidney Disease

Type2diabetesDiabetic Kidney Disease

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Recruiting22 enrollment criteria

Exercise Study Testing Enhanced Energetics of Mitochondria Video Integrated Delivery of Activity...

Moderate-severe Chronic Kidney Disease Not Treated With DialysisDiabetic Kidney Disease1 more

Skeletal muscle dysfunction (sarcopenia) is an under-recognized target organ complication of CKD with substantial adverse clinical consequences of disability, hospitalization, and death. Sarcopenia in this proposal is defined by impaired metabolism and physical function associated with decreased skeletal muscle mass or function. Skeletal muscle tissue relies on mitochondria to efficiently utilize oxygen to generate ATP. Impaired mitochondrial energetics is a central mechanism of sarcopenia in CKD. The investigators propose a series of studies designed to shed light on the pathophysiology of sarcopenia in persons with CKD not treated with dialysis. Investigators will conduct a randomized-controlled intervention trial of combined resistance training and aerobic exercise vs. health education to assess changes in skeletal muscle mitochondrial function, metabolism and physical function. Investigators hypothesize that exercise improves mitochondrial function and physical function in persons with CKD. If successful, these experiments will identify novel pathophysiologic mechanisms for CKD-associated sarcopenia. The proposed study will provide useful insight into benefits associated with exercise among patients with CKD and investigate mechanisms associated with improved metabolism, muscle function and physical function in population.

Recruiting49 enrollment criteria

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease...

Diabetic Kidney DiseaseIgA Nephropathy

This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to matching placebo.

Recruiting39 enrollment criteria

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease...

Kidney Disease

This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.

Recruiting39 enrollment criteria

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic...

Diabetic Nephropathies

The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of the leading causes of mortality from non-communicable diseases. Due to the high prevalence of diabetes and because 30-40% of diabetic patients [both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus] develop kidney dysfunction, diabetic nephropathy (DN) is the main cause of end-stage renal disease worldwide. The renin-angiotensin-aldosterone system (RAAS), endothelin, and urotensin II are vasoactive hormones that have been extensively studied as other mediators although their relation to diabetic nephropathy is still speculative.

Recruiting16 enrollment criteria

Basal Plus GLP1-ra on Glycemic Variability in CKD

Diabetes MellitusDiabetic Kidney Disease

To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4

Recruiting23 enrollment criteria

The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

Type 1 Diabetes MellitusDiabetic Retinopathy1 more

The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.

Recruiting28 enrollment criteria

Targeting Leukotrienes in Kidney Disease

Diabetic Kidney Disease

Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.

Recruiting22 enrollment criteria

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Renal InsufficiencyChronic1 more

NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR. Because of combination MRA and RAAS therapy significantly increases the risk for clinically significant hyperkalemia, we also plan to determine whether the addition of Patiromer to these patients facilitates the use of combination therapy and allows a larger proportion of diabetic patients the potential benefit of combination therapy on renal function.

Recruiting23 enrollment criteria
1234...43

Need Help? Contact our team!


We'll reach out to this number within 24 hrs